Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE and next-generation, highly selective ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

At 12, you could eat an entire pizza, chase it with ice cream, and still be hungry an hour later. Your metabolism was a ...

Allschwil, Switzerland - January 12, 2026Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conference ...

Advancing investigational pre-clinical research of APL-9099 3, a potential one-time neonatal Fc receptor (FcRn) treatment ...